Federal Circuit vacates injunction in Amgen’s dispute with Sanofi
The permanent injunction granted by the District of Delaware in the dispute between Amgen and Sanofi/Regeneron over cholesterol-lowering treatment has been vacated, in a decision that also included some implications for the USPTO’s practice of granting broad antibody claims
The Federal Circuit has vacated the permanent injunction in the dispute between Amgen and Sanofi/Regeneron over cholesterol-lowering treatment.
Sanofi and Regeneron Pharmaceuticals appealed a final judgment of the District of Delaware in January that held that two patents were...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.